Healthcare Apr 26, 2022 11:11 AM (GMT+8) · EqualOcean
Recently, in Bojian has decided to withdraw the marketing authorization application submitted in Europe. At the previous expert meeting, the European Drug Commission told Bojian that the clinical efficacy data of aduhelm provided by the company were not enough to support its potential approval. Last December, CHMP voted explicitly against the regulatory authorization of this controversial Alzheimer's disease drug.